Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMS 232632

Known as: 232632, BMS, BMS-232632, BMS232632 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
A selective, accurate, and reproducible LC-MS-MS assay was developed for the determination of the HIV protease inhibitor… Expand
Is this relevant?
2003
2003
A selective, accurate, and reproducible LC/MS/MS assay was developed and validated for the determination of the HIV protease… Expand
Is this relevant?
2002
2002
ABSTRACT The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other… Expand
  • table 1
  • table 2
  • figure 1
Is this relevant?
2001
2001
BMS-232632 is a potent human immunodeficiency type 1 (HIV-1) protease inhibitor with a half-life that allows for once-daily… Expand
  • figure 1
  • figure 2
Is this relevant?
2001
2001
  • G. Witherell
  • Current opinion in investigational drugs
  • 2001
  • Corpus ID: 21294499
BMS-232632, an azapeptide HIV protease inhibitor, is in development by Bristol-Myers Squibb (BMS), under license from Novartis… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
ABSTRACT BMS-232632 is an azapeptide human immunodeficiency virus type 1 (HIV-1) protease (Prt) inhibitor that exhibits potent… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
ABSTRACT BMS-232632 is an azapeptide human immunodeficiency virus (HIV) type 1 (HIV-1) protease inhibitor that displays potent… Expand
Is this relevant?
2000
2000
  • G Gaylord
  • Positive living
  • 2000
  • Corpus ID: 35225585
 
Is this relevant?